Reflections on 2024’s Progress in R/R CLL

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

EP: 1.Fixed-Duration Options for CLL

EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study

EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

EP: 4.Sequencing Considerations in Relapsed/Refractory CLL

EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors

EP: 8.Switching Between BTK Inhibitors in CLL

EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity

EP: 10.Opportunities for Easing BTK Inhibitor Switches

Now Viewing

EP: 11.Reflections on 2024’s Progress in R/R CLL

Related Videos

Related Content

Advertisement

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 13th 2025

Cuts to PEPFAR Spell Detrimental HIV Outcomes in South Africa

Julia Bonavitacola

HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 12th 2025

Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval

Giuliana Grossi

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral solution.

February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.

Related Content

Advertisement

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 13th 2025

Cuts to PEPFAR Spell Detrimental HIV Outcomes in South Africa

Julia Bonavitacola

HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 12th 2025

Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval

Giuliana Grossi

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral solution.

February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.